Photocarcinogenesis of topical tazarotene and isotretinoin alone and in combination with valproic acid in hairless mice

Experimental Dermatology

Volumn 17, Issue 11, 2008, Pages 972-974

  Lerche, Catharina M ^a   Philipsen, Peter A ^a   Sehested, Maxwell ^b,c   Wulf, Hans Christian ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Rigshospitalet   (Denmark)

^c BioAlliance Pharma   (France)

Author keywords

Hairless mice; Isotretinoin; Photocarcinogenesis; Tazarotene; Valproic acid

Indexed keywords

BACECA; ISOTRETINOIN; TAZAROTENE; UNCLASSIFIED DRUG; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DEATH; DRUG CARCINOGENICITY; DRUG EFFICACY; FEMALE; FOLLOW UP; HAIRLESS MOUSE; IMMUNOCOMPETENCE; MONOTHERAPY; MOUSE; NONHUMAN; RADIATION PROTECTION; SKIN PROTECTION; SKIN TUMOR; SOLAR RADIATION;

ADMINISTRATION, CUTANEOUS; ANIMALS; CARCINOGENS; DERMATOLOGIC AGENTS; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; ISOTRETINOIN; KAPLAN-MEIERS ESTIMATE; MICE; MICE, HAIRLESS; NICOTINIC ACIDS; PHOTOCHEMICAL PROCESSES; SKIN; SKIN NEOPLASMS; ULTRAVIOLET RAYS; VALPROIC ACID;

EID: 54049090433     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/j.1600-0625.2008.00733.x     Document Type: Article

References (30)

1. Altucci L, Gronemeyer H. The promise of retinoids to fight against cancer. Nat Rev Cancer 2001: 1: 181-193.
2. Bug G, Ritter M, Wassmann B et al. Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia. Cancer 2005: 104: 2717-2725.
3. Cimino G, Lo-Coco F, Fenu S et al. Sequential valproic acid/all-trans retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemia. Cancer Res 2006: 66: 8903-8911.
4. Kuendgen A, Schmid M, Schlenk R et al. The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. Cancer 2006: 106: 112-119.
5. Mongan N P, Gudas L J. Valproic acid, in combination with all-trans retinoic acid and 5-aza-2′-deoxycytidine, restores expression of silenced RARbeta2 in breast cancer cells. Mol Cancer Ther 2005: 4: 477-486.
6. Kramer O H, Zhu P, Ostendorff H P et al. The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. EMBO J 2003: 22: 3411-3420.
7. Kurdistani S K. Histone modifications as markers of cancer prognosis: A cellular view. Br J Cancer 2007: 97: 1-5.
8. Blaheta R A, Michaelis M, Driever P H et al. Evolving anticancer drug valproic acid: Insights into the mechanism and clinical studies. Med Res Rev 2005: 25: 383-397.
9. Lerche C M, Philipsen P A, Poulsen T et al. Topical tacrolimus in combination with simulated solar radiation does not enhance photocarcinogenesis in hairless mice. Exp Dermatol 2008: 17: 57-62.
10. Diffey B L, Jansen C T, Urbach F et al. The standard erythema dose: A new photobiological concept. Photodermatol Photoimmunol Photomed 1997: 13: 64-66.
11. Hedelund L, Lerche C, Wulf H C et al. Carcinogenesis related to intense pulsed light and UV exposure: An experimental animal study. Lasers Med Sci 2006: 21: 198-201.
12. S, Leyden J J, Lowe N J et al. Tazarotene cream for the treatment of facial photodamage: A multicenter, investigator-masked, randomized, vehicle-controlled, parallel comparison of 0.01%, 0.025%, 0.05%, and 0.1% tazarotene creams with 0.05% tretinoin emollient cream applied once daily for 24weeks. Arch Dermatol 2001: 137: 1597-1604.
13. Wulf H C, Poulsen T, Brodthagen H et al. Sunscreens for delay of ultraviolet induction of skin tumors. J Am Acad Dermatol 1982: 7: 194-202.
14. Finnin M S, Donigian J R, Cohen A et al. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 1999: 401: 188-193.
15. Glauben R, Batra A, Fedke I et al. Histone hyperacetylation is associated with amelioration of experimental colitis in mice. J Immunol 2006: 176: 5015-5022.
16. Puhvel S M, Sakamoto M. Effect of topical application of 13-cis retinoic acid on skin of hairless rats and hairless mice. Arch Dermatol Res 1985: 277: 395-399.
17. Peck G L, DiGiovanna J J, Sarnoff D S et al. Treatment and prevention of basal cell carcinoma with oral isotretinoin. J Am Acad Dermatol 1988: 19: 176-185.
18. Bollag W. Prophylaxis of chemically induced papillomas and carcinomas of mouse skin by vitamin A-acid. Experientia 1972: 28: 1219-1220.
19. Kligman L H. Retinoic acid and photocarcinogenesis - a controversy. Photodermatology 1987: 4: 88-101.
20. Kligman L H. Tretinoin and photocarcinogenicity - an update. J Toxicol Cutaneous Ocul Toxicol 1993: 12: 205-220.
21. Forbes P D, Urbach F, Davies R E. Enhancement of experimental photocarcinogenesis by topical retinoic acid. Cancer Lett 1979: 7: 85-90.
22. Epstein J H. Chemicals and photocarcinogenesis. Australas J Dermatol 1977: 18: 57-61.
23. Connor M J, Lowe N J, Breeding J H et al. Inhibition of ultraviolet-B skin carcinogenesis by all-trans-retinoic acid regimens that inhibit ornithine decarboxylase induction. Cancer Res 1983: 43: 171-174.
24. Epstein J H, Grekin D A. Inhibition of ultraviolet-induced carcinogenesis by all-trans retinoic acid. J Invest Dermatol 1981: 76: 178-180.
25. Kligman L H, Kligman A M. Lack of enhancement of experimental photocarcinogenesis by topical retinoic acid. Arch Dermatol Res 1981: 270: 453-462.
26. Kraemer K H, DiGiovanna J J, Peck G L. Chemoprevention of skin cancer in xeroderma pigmentosum. J Dermatol 1992: 19: 715-718.
27. Kraemer K H, DiGiovanna J J, Moshell A N et al. Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin. N Engl J Med 1988: 318: 1633-1637.
28. Nagpal S, Chandraratna R A. Recent developments in receptor-selective retinoids. Curr Pharm Des 2000: 6: 919-931.
29. Peris K, Fargnoli M C, Chimenti S. Preliminary observations on the use of topical tazarotene to treat basal-cell carcinoma. N Engl J Med 1999: 341: 1767-1768.
30. So P L, Lee K, Hebert J et al. Topical tazarotene chemoprevention reduces basal cell carcinoma number and size in Ptch1+/-mice exposed to ultraviolet or ionizing radiation. Cancer Res 2004: 64: 4385-4389.